NCT01189396View on ClinicalTrials.gov

Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

January 31, 2011

Conditions
AsthmaBronchospasmChronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

A006

Albuterol DPI with 180 mcg Albuterol/inhalation

DRUG

Placebo DPI

Placebo DPI with 0 mcg Albuterol/inhalation

DRUG

Proventil-HFA

Albuterol MDI with 90 mcg Albuterol/inhalation

Trial Locations (4)

78229

Amphastar Site 0032, San Antonio

97213

Amphastar Site 0026, Portland

97504

Amphastar Site 0025, Medford

98105

Amphastar Site 0034, Seattle

Sponsors
All Listed Sponsors
lead

Amphastar Pharmaceuticals, Inc.

INDUSTRY